See the DrugPatentWatch profile for cosentyx

While I cannot directly answer why Cosentyx doses are higher for obese patients without access to specific clinical guidelines or studies, I can provide some context that might help explain this.

Cosentyx (secukinumab) is a biologic medication used to treat several conditions, including psoriasis, psoriatic arthritis, and ankylosing spondylitis [1]. The drug's effectiveness is based on its ability to inhibit a specific protein involved in inflammation, interleukin-17A [1].

Obesity can impact drug pharmacokinetics, or how a drug moves through the body, by altering factors such as drug absorption, distribution, metabolism, and excretion [2]. In some cases, these changes can lead to altered drug efficacy or increased risk of adverse effects [2]. Consequently, higher doses may be required to achieve the desired therapeutic effect in obese patients.

However, it is essential to note that drug dosing regimens are typically determined based on clinical trials and pharmacokinetic studies [2]. Therefore, any differences in Cosentyx dosing between obese and non-obese patients would likely be supported by evidence from these studies.

To obtain more specific information on why Cosentyx doses are higher for obese patients, it would be necessary to consult clinical guidelines, drug labels, or relevant scientific literature.

Sources:
[1] Cosentyx (secukinumab) [DrugPatentWatch.com]
[2] Obesity and Pharmacokinetics | FDA